Prevalence of Transmitted HIV Drug Resistance in Iran between 2010 and 2011

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Jahanbakhsh, Fatemeh ^a,b   Hattori, Junko ^c   Matsuda, Masakazu ^c   Ibe, Shiro ^c   Monavari, Seyed Hamid R ^a   Memarnejadian, Arash ^b   Aghasadeghi, Mohammad R ^b   Mostafavi, Ehsan ^b   Mohraz, Minoo ^d   Jabbari, Hossain ^d,e   Kamali, Kianoush ^f   Keyvani, Hossein ^a   Azadmanesh, Kayhan ^b   Sugiura, Wataru ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; P17 GAG PEPTIDE, HUMAN IMMUNODEFICIENCY VIRUS; PEPTIDE FRAGMENT; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENVELOPE GENE; FEMALE; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IRAN; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; STRUCTURAL GENE; VIRUS MUTATION; VIRUS TRANSMISSION; ADOLESCENT; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; MUTATION; PREVALENCE; RETROSPECTIVE STUDY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENES, ENV; HIV INFECTIONS; HIV INTEGRASE; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IRAN; MALE; MUTATION; PEPTIDE FRAGMENTS; PHYLOGENY; PREVALENCE; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 84876551283     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061864     Document Type: Article

References (20)

1. Popp D, Fisher JD, (2002) First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. AIDS 16: 676-678.
2. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF, (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13Suppl 2: 25-36.
3. National AIDS Committee Secretariat,Ministry of Health and Medical Education.Islamic Repoblic of Iran (2008) Progress Report on Monitoring of United Nations General Assembly Special Session (UNGASS) on HIV and AIDS.
4. Ministry of Health and Medical Education (MHME), Iran, (March 2012) AIDS/HIV surveillance report, MHME, Tehran.
5. Vazirian M, Nassirimanesh B, Zamani S, Ono-Kihara M, Kihara M, et al. (2005) Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: a cross-sectional study. Harm Reduct J 2: 19.
6. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, et al. (2005) Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS 19: 709-716.
7. National AIDS Committee Secretariat, Ministry of Health and Medical Education.(updated March 2012) Islamic Republic of Iran Progress Report on Monitoring of the United Nations General Assembly Special Session (UNGASS) on HIV and AIDS.
8. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, et al. (2008) World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 13Suppl 2: 49-57.
9. Sugiura W, Matsuda M, Abumi H, Yamada K, Taki M, et al. (1999) Prevalence of drug resistance-related mutations among HIV-1s in Japan. Jpn J Infect Dis 52: 21-22.
10. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
11. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
12. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164.
13. Mousavi SM, Hamkar R, Gouya MM, Safaie A, Zahraei SM, et al. (2010) Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study. Arch Virol 155: 329-334.
14. Soheilli ZS, Ataiee Z, Tootian S, Zadsar M, Amini S, et al. (2009) Presence of HIV-1 CRF35_AD in Iran. AIDS Res Hum Retroviruses 25: 123-124.
15. Naderi HR, Tagliamonte M, Tornesello ML, Ciccozzi M, Rezza G, et al. (2006) Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran. Infect Agent Cancer 1: 4.
16. Sarrami-Forooshani R, Das SR, Sabahi F, Adeli A, Esmaeili R, et al. (2006) Molecular analysis and phylogenetic characterization of HIV in Iran. J Med Virol 78: 853-863.
17. Tagliamonte M, Naderi HR, Tornesello ML, Farid R, Buonaguro FM, et al. (2007) HIV type 1 subtype A epidemic in injecting drug user (IDU) communities in Iran. AIDS Res Hum Retroviruses 23: 1569-1574.
18. Myatt M, Bennett DE, (2008) A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 13Suppl 2: 37-48.
19. Applebaum AJ, Reilly LC, Gonzalez JS, Richardson MA, Leveroni CL, et al. (2009) The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care STDS 23: 455-462.
20. Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, et al. (2004) Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 45: 394-402.